MyoKardia to Present at 2019 Cantor Global Healthcare Conference
September 26, 2019 16:05 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will participate in a fireside chat at...
MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients
September 10, 2019 08:44 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy...
MyoKardia Presents 36-week Data from PIONEER-OLE Study of Mavacamten at the European Society of Cardiology Congress 2019
August 31, 2019 05:00 ET
|
MyoKardia, Inc.
Durability of Mavacamten's Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, Obstructive HCM Statistically Significant Changes in Key Biomarkers...
MyoKardia to Participate in September Investor Conferences
August 28, 2019 16:05 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced its participation in the following upcoming investor conferences: Citi 14th Annual...
MyoKardia Announces Abstracts Selected for Presentation at the European Society of Cardiology Congress 2019
August 26, 2019 08:30 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the presentation of three abstracts at the upcoming European Society of Cardiology (ESC)...
MyoKardia Begins Dosing in Phase 1 Clinical Study of MYK-224 for Hypertrophic Cardiomyopathy
August 21, 2019 08:30 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small...
MyoKardia Launches 2nd Annual MyoSeeds™ Research Grants Program to Advance Independent Research in Heart Disease
August 15, 2019 08:30 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. today announced the launch of the 2nd Annual MyoSeeds™ Research Grants Program, an initiative to support original,...
MyoKardia Reports Second Quarter 2019 Financial Results
August 07, 2019 16:05 ET
|
MyoKardia, Inc.
Announces Last Patient to be Enrolled in EXPLORER-HCM Phase 3 during the Week of August 12th; Topline Data Accelerated to 2nd Quarter 2020 Topline Phase 2 Clinical Data from MAVERICK-HCM and MYK-491...
MyoKardia to Present at 2019 Wedbush PacGrow Healthcare Conference
August 07, 2019 08:00 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will present at the 2019 Wedbush PacGrow...
MyoKardia to Report Second Quarter 2019 Financial Results on Wednesday, August 7, 2019
July 31, 2019 16:05 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report second quarter 2019 financial and operating results on Wednesday,...